Cargando…

Low value of detection of KRAS2 mutations in circulating DNA to differentiate chronic pancreatitis to pancreatic cancer

Detalles Bibliográficos
Autores principales:	Marchese, R, Muleti, A, Brozzetti, S, Gandini, O, Brunetti, E, French, D
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2004
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409514/ https://www.ncbi.nlm.nih.gov/pubmed/15150585 http://dx.doi.org/10.1038/sj.bjc.6601854

Ejemplares similares

Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA
por: Maire, F, et al.
Publicado: (2002)

Diagnostic and Prognostic Values of KRAS Mutations on EUS-FNA Specimens and Circulating Tumor DNA in Patients With Pancreatic Cancer
por: Wang, Ronghua, et al.
Publicado: (2022)

KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control
por: Le Calvez-Kelm, Florence, et al.
Publicado: (2016)

Optimal value of CA19-9 determined by KRAS-mutated circulating tumor DNA contributes to the prediction of prognosis in pancreatic cancer patients
por: Watanabe, Fumiaki, et al.
Publicado: (2021)

The value of KRAS mutation testing with CEA for the diagnosis of pancreatic mucinous cysts
por: Kadayifci, Abdurrahman, et al.
Publicado: (2016)

Pancreatic cancer: Circulating Tumor Cells and Primary Tumors show Heterogeneous KRAS Mutations
por: Kulemann, Birte, et al.
Publicado: (2017)

Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome
por: Lemstrova, Radmila, et al.
Publicado: (2017)

Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer
por: Watanabe, Fumiaki, et al.
Publicado: (2019)

Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients
por: Cheng, He, et al.
Publicado: (2020)

Circulating tumour-derived KRAS mutations in pancreatic cancer cases are predominantly carried by very short fragments of cell-free DNA
por: Zvereva, Maria, et al.
Publicado: (2020)

Pancreatic cyst fluid harboring a KRAS mutation
por: Al-Turkmani, M. Rabie, et al.
Publicado: (2019)

Evaluation of the Prognostic Value of Low-Frequency KRAS Mutation Detection in Circulating Tumor DNA of Patients with Metastatic Colorectal Cancer
por: Lin, Chien-Yu, et al.
Publicado: (2023)

Author Correction: Pancreatic cancer: Circulating Tumor Cells and Primary Tumors show Heterogeneous KRAS Mutations
por: Kulemann, Birte, et al.
Publicado: (2017)

Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer
por: Mohan, Sumitra, et al.
Publicado: (2019)

Highlights on the Role of KRAS Mutations in Reshaping the Microenvironment of Pancreatic Adenocarcinoma
por: Hafezi, Shirin, et al.
Publicado: (2021)

Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma
por: Liu, Yu-Huei, et al.
Publicado: (2022)

KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression
por: Zhang, Zining, et al.
Publicado: (2023)

Kras mutation rate precisely orchestrates ductal derived pancreatic intraepithelial neoplasia and pancreatic cancer
por: Singh, Kanchan, et al.
Publicado: (2020)

Targeting KRAS in Pancreatic Cancer
por: Cowzer, Darren, et al.
Publicado: (2022)

KRAS Mutant Allele Fraction in Circulating Cell-Free DNA Correlates With Clinical Stage in Pancreatic Cancer Patients
por: Wang, Zhe-Ying, et al.
Publicado: (2019)

Impact of KRAS Mutations and Co-mutations on Clinical Outcomes in Pancreatic Ductal Adenocarcinoma
por: Yousef, Abdelrahman, et al.
Publicado: (2023)

Correction to: Kras mutation rate precisely orchestrates ductal derived pancreatic intraepithelial neoplasia and pancreatic cancer
por: Singh, Kanchan, et al.
Publicado: (2021)

Circulating tumor cells (CTC) and KRAS mutant circulating free DNA (cfDNA) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer
por: Earl, Julie, et al.
Publicado: (2015)

Differential Cell Susceptibilities to Kras(G12D) in the Setting of Obstructive Chronic Pancreatitis
por: Shi, Chanjuan, et al.
Publicado: (2019)

Prognostic value of absolute quantification of mutated KRAS in circulating tumour DNA in lung adenocarcinoma patients prior to therapy
por: Wahl, Sissel Gyrid Freim, et al.
Publicado: (2021)

The Mutational Landscape of Pancreatic and Liver Cancers, as Represented by Circulating Tumor DNA
por: Rice, Alistair, et al.
Publicado: (2019)

Oncogenic KRAS signalling in pancreatic cancer
por: Eser, S, et al.
Publicado: (2014)

KRAS mutations as essential promoters of lymphangiogenesis via extracellular vesicles in pancreatic cancer
por: Pirlog, Radu, et al.
Publicado: (2022)

Mutant KRAS and GNAS DNA Concentrations in Secretin-Stimulated Pancreatic Fluid Collected from the Pancreatic Duct and the Duodenal Lumen
por: Sadakari, Yoshihiko, et al.
Publicado: (2014)

KRAS above and beyond – EGFR in pancreatic cancer
por: Siveke, Jens T., et al.
Publicado: (2012)

Beyond Kras: MYC Rules in Pancreatic Cancer
por: Korc, Murray
Publicado: (2018)

Zebrafish model of KRAS-initiated pancreatic cancer
por: Park, Joon Tae, et al.
Publicado: (2018)

Comparison of KRAS Mutation Assessment in Tumor DNA and Circulating Free DNA in Plasma and Serum Samples
por: Morgan, Shethah R., et al.
Publicado: (2012)

Pancreatic duct ligation reduces premalignant pancreatic lesions in a Kras model of pancreatic adenocarcinoma in mice
por: Cáceres, Marta, et al.
Publicado: (2020)

Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer
por: Hadano, Naoto, et al.
Publicado: (2016)

KRAS Mutation Dictates the Cancer Immune Environment in Pancreatic Ductal Adenocarcinoma and Other Adenocarcinomas
por: Gu, Meichen, et al.
Publicado: (2021)

KRAS variant allele frequency, but not mutation positivity, associates with survival of patients with pancreatic cancer
por: Suzuki, Tatsunori, et al.
Publicado: (2022)

Diagnostic value of imaging examination in autoimmune pancreatitis
por: Wang, Fang, et al.
Publicado: (2022)

Surgical-only treatment of pancreatic and extra-pancreatic metastases from renal cell carcinoma - quality of life and survival analysis
por: Brozzetti, Stefania, et al.
Publicado: (2020)

KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer
por: Sclafani, Francesco, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2ksdq4o5c4n21jkvpe71tddnoi